ABUS vs CUBE
Arbutus Biopharma Corp (ABUS) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the ABUS and CUBE stock pages for the full models.
Not investment advice.